Identification of Archaea Associated with Recovery from Antibiotic Exposure

Anne Lemek - Senior

ABSTRACT

Dysbiosis, or a microbial imbalance, of the human gut microbiome has been associated with numerous immunological and neurological disorders. Antibiotic exposure, among others, is one of the leading causes of gut dysbiosis, and can lead to increased risk of health issues if the gut microbiome does not recover after exposure. However, there may be microbiota normally present that aid in recovery from antibiotic-exposure, including fungi and archaeal species. This study focused on determining if there are fungi or archaea associated with gut recovery by comparing the detected presence of archaea in hosts that have recovered and not recovered from antibiotic exposure. The results indicate that there are no fungal or archaeal species associated with recovery from antibiotic-exposure.

METHODOLOGY

Data Accession and Analysis:

 Data uploaded to Qiita¹¹ from "The initial state of the human gut microbiome determines its reshaping by antibiotics"¹²

Identification of Gut Microbiota:

- Gut microbiota determined through kingdom and species level barplots

Recovery Determination:

Diversity levels across three time points (Day 0, 7, and 90: pre-, during-, and post-exposure respectively) determined using Simpson's


DISCUSSION

Lack of Fungal Presence

As expected, the majority of the samples were made up of bacterial species. However, there was no fungal presence detected in any of the samples, suggesting that the original hypothesis is not supported. However, for there to be no fungal species found in any of the samples is strange. There are a few possible explanations:

- **1.** Fungi are not a normal gut microbiota
- The fungal species present were not able to be classified by the Qiita software.
- **3.** The sequencing process that produced the data was mislabelled as metagenomic, when it should have been 165 (automates do not have 165)

INTRODUCTION



Diversity Test

- Recoverers: similar or higher diversity at Day 90 as seen at Day 0
- Non-Recoverers: lower diversity at Day 90 as seen as Day 0

Identification of Recovery-Associated Archaea:

- Two-tailed student *t*-test performed between recoverers, non-recoverers at each timepoint
- Hypotheses used were H_0 : $\mu_1 = \mu_2$ and H_A : $\mu_1 \neq \mu_{2,2}$, alpha level of 0.1.

RESULTS

Taxonomic Kingdoms Present in Samples	
	k_Bacteria k_Archaea
100%	
75%	
50%	

Microbiota

The only two kingdoms found to be present in the samples were Bacteria (99% to 100% of the sample depending on the have been 16S (eukaryotes do not have 16S rRNA)

Archaeal Association with Recovery While there was no detected fungal presence, there were archaeal species detected, and the focus of the study shifted to determining how archaea are associated with recovery. Though the differences between each of the top five species of non-recoverers and recoverers for each time point seemed significant, all student t-tests resulted in p-values much greater than the alpha level of 0.1. As such, the null hypothesis that the mean values of the five species are not different between recoverers and non-recoverers must be accepted. This suggests that there are no archaeal species associated with recovery from antibiotic exposure.

CONCLUSION

- Hypothesis not supported: no fungi present in any sample, no fungi associated with recovery from antibiotics
- No archaeal species that appear to be associated with recovery from antibiotics
- Future work: look at more samples for fungal presence and look at split between archaeal and bacterial diversity

GMFH Editing Team GMFH Editing Team. (2020, March 24). The knowns and unknowns of the human microbiome. Retrieved May 11, 2021, from https://www.gutmicrobiotaforhealth.com/the-knowns-and-unknowns-of-the-hum an-microbiome/


The Human Microbiome

The human microbiome is a complex system of microorganisms unique to each individual that plays an important role in maintaining host health⁽¹⁾. An imbalance in this microbial community is called dysbiosis. In the human gut microbiome, dysbiosis has been associated with a multitude of disorders, diseases and immune dysfunction⁽²⁾⁽³⁾⁽⁴⁾.

Antibiotic Use and Gut Dysbiosis


One major cause of gut dysbiosis is the usage of antibiotics. Antibiotic use disrupts the levels of pathogenic and commensal microbes, allowing for the formation of empty niches that can be filled by pathogens or an overgrowth of normal flora⁽⁵⁾. Studies have suggested that the long-term effects of antibiotic usage may include increased risk of infection⁽⁶⁾ and metabolic disease⁽⁷⁾.

Fungi in Gut Microbiome



Microbial Diversity


Using the data from the Simpson's Diversity Index, the samples were sorted into recoverers and non-recoverers. Recoverers showed a similar or higher diversity after exposure as they showed prior to exposure (P2, P9, P10, P11, P12, P13, P17, P21, P22). Non-recoverers showed a lower diversity after exposure compared to prior to exposure (P1, P5, P15, P18, P19, P20).



Microbial Diversity of Recoverers



Microbial Diversity of Non-Recoverers



REFERENCES

- Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D., Hirschfield, G. M., Hold, G., ... & Thomas, L. V. (2016). The gut microbiota and host health: a new clinical frontier. *Gut*, 65(2), 330-339.
- Kostic, A. D., Xavier, R. J., & Gevers, D. (2014). The microbiome in inflammatory bowel disease: current status and the future ahead. *Gastroenterology*, *146*(6), 1489-1499.
- Gilbert, J. A., Quinn, R. A., Debelius, J., Xu, Z. Z., Morton, J., Garg, N., ...
 & Knight, R. (2016). Microbiome-wide association studies link dynamic microbial consortia to disease. *Nature*, *535*(7610), 94-103.
- Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P., Alou, M. T., Daillère, R., ... & Fidelle, M. (2018). Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. *Science*, 359(6371), 91-97.
- 5. Donskey, C. J. (2004). The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. *Clinical infectious diseases*, *39*(2), 219-226.
- 6. Langdon, A., Crook, N., & Dantas, G. (2016). The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. *Genome medicine*, *8*(1), 39.
- Cox, L. M., & Blaser, M. J. (2015). Antibiotics in early life and obesity. Nature Reviews Endocrinology, 11(3), 182.
- Hamad, I., Raoult, D., & Bittar, F. (2016). Repertory of eukaryotes (eukaryome) in the human gastrointestinal tract: taxonomy and detection methods. *Parasite immunology*, *38*(1), 12-36.
- 9. Al Bataineh, M. T., Dash, N. R., Lassen, P. B., Banimfreg, B. H., Nada, A.

The role of bacteria and its interaction with antibiotics in the gut microbiome has been extensively studied, but the role of fungi in the gut microbiome has not. Just under 280 fungal species have been identified in the gut microbiome⁽⁸⁾, but dysbiosis of the fungal communities has been associated with diseases such as Type 2 diabetes mellitus⁽⁹⁾ and bacterial keratitis⁽¹⁰⁾. Fungi appear to play an important role in host health, and the loss of normal bacteria may cause issues from fungal overgrowth.

HYPOTHESIS

There are fungal species associated with gut microbiome recovery from cefprozil.

Day 0 Results

Top five most prevalent species: *M. smithii, M. smithii CAG:186, M. millerae, M. mazei, M. archeon Phil4* (recoverer-specific), and *M. archeon Methan_05* (non-recoverer-specific). The respective p-values :0.55, 0.55, 0.58, 0.39, 0.52, and 0.36. **Day 7 Results**

The top five most prevalent species:*M. smithii, M. smithii CAG:186, M. mazei, M. archeon Phil4, M. millerae* (recoverer-specific),and *M. archeon Methan_05* (non-recoverer-specific). The respective p-values: 0.96, 0.95, 0.52, 0.48, 0.82, and 0.36. **Day 90 Results**

The top five most prevalent species: *M. smithii, M. smithii CAG:186, M. mazei, M. archeon Phil4, S. acidocaldarius* (recoverer-specific) and *M. archeon Methan_05* (non-recoverer-specific).

The respective p-values:0.94, 0.92, 0.42, 0.90, 0.32, and 0.47.

- M. Balamen, M. T., Dasn, N. K., Lassen, P. B., Balamineg, B. H., Nada, A.
 M., Belda, E., & Clément, K. (2020). Revealing links between gut microbiome and its fungal community in Type 2 Diabetes Mellitus among Emirati subjects: A pilot study. *Scientific reports*, *10*(1), 1-11.
- Jayasudha, R., Chakravarthy, S. K., Prashanthi, G. S., Sharma, S., Garg, P., Murthy, S. I., & Shivaji, S. (2018). Alterations in gut bacterial and fungal microbiomes are associated with bacterial Keratitis, an inflammatory disease of the human eye. *Journal of biosciences*, *43*(5), 835-856.
- Gonzalez, A., Navas-Molina, J. A., Kosciolek, T., McDonald, D., Vázquez-Baeza, Y., Ackermann, G., ... & Sanders, J. G. (2018). Qiita: rapid, web-enabled microbiome meta-analysis. *Nature methods*, *15*(10), 796-798.
- 12. Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., ...
 & Mende, D. R. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. *nature*, *464*(7285), 59-65.

ACKNOWLEDGEMENTS

- The Qiita Help Team
- Dr. Anthony Hay
- Mr Seweryn
- My parents